Any feedback?
Please rate this page

BRENDA support

Disease on EC - cholinesterase and Organism(s) Homo sapiens

for references in articles please use BRENDA:EC3.1.1.8

Please use the Disease Search for a specific query.

Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Abortion, Spontaneous
Butyrylcholinesterase activity and lymphocyte subpopulations in peripheral blood of Kuwaiti women experiencing recurrent spontaneous abortion.
Ratio of immunochemically determined amniotic fluid acetylcholinesterase to butyrylcholinesterase in the differential diagnosis of fetal abnormalities.
Abortion, Threatened
[Changes in the concentration of copper and ceruloplasmin, and cholinesterase activity in the blood in threatened abortion]
acetylcholinesterase deficiency
Congenital myasthenic syndromes.
[Congenital myasthenic syndromes: phenotypic expression and pathophysiological characterisation]
Chronotropic and dromotropic actions of acetylcholine on the developing fetal heart.
Organophosphate poisoning: modifications in acid base equilibrium and use of sodium bicarbonate as an aid in the treatment of toxicity in dogs.
Suspected chlorpyrifos toxicosis in a llama, and plasma pseudocholinesterase activity in llamas given chlorpyrifos.
[Severe medical sequelae in heroin addicts]
Acidosis, Lactic
Acute toxicity of methyl isocyanate in mammals. II. Induction of hyperglycemia, lactic acidosis, uraemia, and hypothermia in rats.
Acne Vulgaris
Safety and efficacy of mTOR inhibitor treatment in patients with tuberous sclerosis complex under 2?years of age - a multicenter retrospective study.
Acquired Immunodeficiency Syndrome
Butyrylcholinesterase Levels on Admission Predict Severity and 12-Month Mortality in Hospitalized AIDS Patients.
Concentrations of magnesium, zinc and copper in serum of patients with acquired immuno-deficiency syndrome.
[Research on risk factors of short-term outcome in AIDS patients with pneumocystis pneumonia].
The evaluation of hypothalamic somatostatin tone using pyridostigmine and thyrotropin releasing hormone in patients with acromegaly.
Acute Coronary Syndrome
Butyrylcholinesterase Activity Predicts Long-Term Survival in Patients with Coronary Artery Disease.
Butyrylcholinesterase predicts cardiac mortality in young patients with acute coronary syndrome.
Low Serum-Butyrylcholinesterase Activity as a Prognostic Marker of Mortality Associates with Poor Cardiac Function in Acute Myocardial Infarction.
Acute Kidney Injury
Activation of ?7 Nicotinic Acetylcholine Receptor Ameliorates Zymosan-Induced Acute Kidney Injury in BALB/c Mice.
Clinical characteristics and outcomes of critically ill COVID-19 patients in Sfax, Tunisia.
Predictors of Morbidity and Mortality in Organophosphorus Poisoning: A Case Study in Rural Hospital in Karnataka, India.
HER-2 amplification but not butyrylcholinesterase multability reflects aggressiveness of European-originated ovarian tumors.
Production of butyrylcholinesterase by Caco-2 cells: lack of relationship with triglyceride production.
Serum pseudocholinesterase levels in murine C3H mammary adenocarcinoma.
Adrenocortical Hyperfunction
Serum paraoxonase 1 and butyrylcholinesterase in dogs with hyperadrenocorticism.
Aggressive Periodontitis
Determination of pseudocholinesterase activity in the gingival crevicular fluid, saliva, and serum from patients with juvenile periodontitis and rapidly progressive periodontitis.
Airway Obstruction
Neostigmine but not sugammadex impairs upper airway dilator muscle activity and breathing.
[Emergency from anesthesia in small children. From laryngospasm to prolonged apnea]
alcohol dehydrogenase deficiency
Ecogenetic and pharmacogenetic studies in Hungary.
Ecogenetic studies in Atacameño Indians.
Alcohol Withdrawal Delirium
[Proceedings: Relationship of serum cholinesterase level in chronic alcoholic liver disease and appearance of delirium tremens: therapeutic effect of oximes]
[Clinical and biochemical alterations in rats treated with high doses of vitamin A]
Alzheimer Disease
"Clicking" fragment leads to novel dual-binding cholinesterase inhibitors.
"Value for money" in treating Alzheimer's disease with the new cholinesterase inhibitors.
(±)-BIGI-3h: Pentatarget-Directed Ligand combining Cholinesterase, Monoamine Oxidase, and Glycogen Synthase Kinase 3? Inhibition with Calcium Channel Antagonism and Antiaggregating Properties for Alzheimer's Disease.
1-Benzylpyrrolidine-3-amine-based BuChE inhibitors with anti-aggregating, antioxidant and metal-chelating properties as multifunctional agents against Alzheimer's disease.
1-N-Substituted thiocarbamoyl-3-phenyl-5-thienyl-2-pyrazolines: a novel cholinesterase and selective monoamine oxidase B inhibitors for the treatment of Parkinson's and Alzheimer's diseases.
11: disorders of memory and intellect.
2-Hydroxy-N-phenylbenzamides and Their Esters Inhibit Acetylcholinesterase and Butyrylcholinesterase.
6-Hydroxy- and 6-methoxy-beta-carbolines as acetyl- and butyrylcholinesterase inhibitors.
9-Substituted acridine derivatives as acetylcholinesterase and butyrylcholinesterase inhibitors possessing antioxidant activity for Alzheimer's disease treatment.
9R, the cholinesterase and amyloid beta aggregation dual inhibitor, as a multifunctional agent to improve cognitive deficit and neuropathology in the triple-transgenic Alzheimer's disease mouse model.
A 10-year perspective on donepezil.
A 12-month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer's disease.
A 24-week, multicentre, open evaluation of the clinical effectiveness of the rivastigmine patch in patients with probable Alzheimer's disease.
A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease.
A case history illustrating how extended release cholinesterase inhibitors could improve management of Alzheimer's disease.
A Case Report on Dyskinesia Following Rivastigmine Patch 13.3 mg/24 hours for Alzheimer's Disease: Perspective in the Movement Disorders Spectrum Following Use of Cholinesterase Inhibitors.
A case with cholinesterase inhibitor responsive asymmetric posterior cortical atrophy.
A clinical overview of cholinesterase inhibitors in Alzheimer's disease.
A critical review of cholinesterase inhibitors as a treatment modality in Alzheimer's disease.
A double-blind crossover pilot study of l-deprenyl (selegiline) combined with cholinesterase inhibitor in Alzheimer's disease.
A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group.
A fixed-dose combination of memantine extended-release and donepezil in the treatment of moderate-to-severe Alzheimer's disease.
A gorge-spanning, high-affinity cholinesterase inhibitor to explore beta-amyloid plaques.
A large, naturalistic, community-based study of rivastigmine in mild-to-moderate AD: the EXTEND Study.
A longitudinal study of risk factors for community-based home help services in Alzheimer's disease: the influence of cholinesterase inhibitor therapy.
A modified binary particle swarm optimization with a machine learning algorithm and molecular docking for QSAR modelling of cholinesterase inhibitors.
A molecular modeling study of components of the ginger (Zingiber officinale) extract inside human butyrylcholinesterase: implications for Alzheimer disease.
A Multi-layered Variable Selection Strategy for QSAR Modeling of Butyrylcholinesterase Inhibitors.
A multicenter double-blind study of controlled-release physostigmine for the treatment of symptoms secondary to Alzheimer's disease. Physostigmine Study Group.
A multifunctional, neuroprotective drug, ladostigil (TV3326), regulates holo-APP translation and processing.
A multiple-dose safety trial of eptastigmine in Alzheimer's disease, with pharmacodynamic observations of red blood cell cholinesterase.
A new therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase.
A new way of data interpretation for cognition tests in rats used to characterise six choline esterase inhibitors with heterocyclic nitrogen bridgehead structure. Application in Alzheimer therapy.
A novel anti-Alzheimer's disease drug, ladostigil neuroprotective, multimodal brain-selective monoamine oxidase and cholinesterase inhibitor.
A novel series of tacrine-selegiline hybrids with cholinesterase and monoamine oxidase inhibition activities for the treatment of Alzheimer's disease.
A palliative care perspective on deprescribing cholinesterase inhibitors in Alzheimer's disease.
A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.
A pharmacoeconomic evaluation of cholinesterase inhibitors and memantine for the treatment of Alzheimer's disease.
A phase II trial of huperzine A in mild to moderate Alzheimer disease.
A Platform for Screening Potential Anticholinesterase Fractions and Components Obtained from Anemarrhena asphodeloides Bge for Treating Alzheimer's Disease.
A population-based study of dosing and persistence with anti-dementia medications.
A potent and selective tacrine analog--biomembrane permeation and physicochemical characterization.
A qualitative analysis of the mini mental state examination on Alzheimer's disease patients treated with cholinesterase inhibitors.
A randomised double-blind placebo-controlled trial of folic acid supplementation of cholinesterase inhibitors in Alzheimer's disease.
A randomised pilot study to assess the efficacy of an interactive, multimedia tool of cognitive stimulation in Alzheimer's disease.
A Randomized Phase I Study of Methanesulfonyl Fluoride, an Irreversible Cholinesterase Inhibitor, for the Treatment of Alzheimer's Disease.
A Randomized Placebo-Controlled Discontinuation Study of Cholinesterase Inhibitors in Institutionalized Patients With Moderate to Severe Alzheimer Disease.
A Real-world Analysis of Treatment Patterns for Cholinesterase Inhibitors and Memantine among Newly-diagnosed Alzheimer's Disease Patients.
A retrospective study of cholinesterase inhibitors for Alzheimer's disease: cerebrovascular disease as a predictor of patient outcomes.
A review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimer's disease.
A review on cholinesterase inhibitors for Alzheimer's disease.
A review on tacrine-based scaffolds as multi-target drugs (MTDLs) for Alzheimer's disease.
A signal detectability analysis of the effect of physostigmine on memory in patients with Alzheimer's disease.
A single nucleotide polymorphism in CHAT influences response to acetylcholinesterase inhibitors in Alzheimer's disease.
A Systematic Review of Practice Guidelines and Recommendations for Discontinuation of Cholinesterase Inhibitors in Dementia.
A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease.
A systematic review of carbohydrate-based bioactive molecules for Alzheimer's disease.
A systematic review on donepezil-based derivatives as potential cholinesterase inhibitors for Alzheimer's disease.
A therapeutic approach to cerebrovascular diseases based on indole substituted hydrazides and hydrazines able to interact with human vascular adhesion protein-1, monoamine oxidases (A and B), AChE and BuChE.
A three-country randomized controlled trial of a psychosocial intervention for caregivers combined with pharmacological treatment for patients with Alzheimer disease: effects on caregiver depression.
A top 5 list for French general practice.
Abhorring the vacuum: use of Alzheimer’s disease medications in frontotemporal dementia.
Acetylcholinergic neurotransmission and the beta-amyloid cascade: implications for Alzheimer's disease.
Acetylcholinesterase activities and monoamine metabolite levels in the cerebrospinal fluid of patients with Alzheimer's disease.
Acetylcholinesterase and butyrylcholinesterase activities in cerebrospinal fluid from different levels of the neuraxis of patients with dementia of the Alzheimer type.
Acetylcholinesterase and butyrylcholinesterase as possible markers of low-grade systemic inflammation.
Acetylcholinesterase and butyrylcholinesterase glycoforms are biomarkers of Alzheimer's disease.
Acetylcholinesterase and butyrylcholinesterase inhibition by nectriapyrone and tryptophol isolated from endophytic fungus Phomopsis sp.
Acetylcholinesterase and butyrylcholinesterase inhibitory activities of khellactone coumarin derivatives isolated from Peucedanum japonicum Thurnberg.
Acetylcholinesterase and butyrylcholinesterase inhibitory activity of Pinus species essential oils and their constituents.
Acetylcholinesterase and its association with heparan sulphate proteoglycans in cortical amyloid deposits of Alzheimer's disease.
Acetylcholinesterase Inhibition of Diversely Functionalized Quinolinones for Alzheimer's Disease Therapy.
Acetylcholinesterase inhibitors, neuropsychiatric symptoms, and Alzheimer's disease subtypes: an alternate hypothesis to global cognitive enhancement.
Acetylcholinesterase inhibitors: SAR and kinetic studies on omega-[N-methyl-N-(3-alkylcarbamoyloxyphenyl)methyl]aminoalkoxyaryl derivatives.
Acetylcholinesterase inhibitory activity of some Amaryllidaceae alkaloids and Narcissus extracts.
Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyze acetylcholine.
Acetylcholinesterase, butyrylcholinesterase, and tyrosinase inhibition studies and antioxidant activities of 33 Scutellaria L. taxa from Turkey.
aChE and BuChE inhibition by rivastigmin have no effect on peripheral insulin resistance in elderly patients with Alzheimer disease.
Acquired Localized Hypertrichosis Induced by Rivastigmine.
Acridine-induced subcellular and functional changes in isolated human hepatocytes in vitro.
Acteylcholinesterase inhibitor rivastigmine enhances cellular defenses in neuronal and macrophage-like cell lines.
Activation of the Cannabinoid Type 2 Receptor by a Novel Indazole Derivative Normalizes the Survival Pattern of Lymphoblasts from Patients with Late-Onset Alzheimer's Disease.
Active compounds from a diverse library of triazolothiadiazole and triazolothiadiazine scaffolds: synthesis, crystal structure determination, cytotoxicity, cholinesterase inhibitory activity, and binding mode analysis.
Activities and kinetic properties of lumbar cerebrospinal fluid cholinesterases in relation to clinical diagnosis, severity, and progression of Alzheimer's disease.
Acute Effects of Muscarinic M1 Receptor Modulation on A?PP Metabolism and Amyloid-? Levels in vivo: A Microdialysis Study.
Acute nicotine effects on auditory sensory memory in tacrine-treated and nontreated patients with Alzheimer's disease: an event-related potential study.
Adherence to cholinesterase inhibitors in Alzheimer's disease: a review.
Adherence to cholinesterase inhibitors in patients with Alzheimer's disease.
Adherence, persistence and continuation with cholinesterase inhibitors in Alzheimer's disease.
Advances in Alzheimer's disease. A review for the family physician.
Advances in the treatment of Alzheimer's disease.
Advances in the treatment of Alzheimer's disease: benefits of dual cholinesterase inhibition.
Advances in the treatment of cognitive impairment in Parkinson's disease.
Adverse drug events affecting medication persistence with rivastigmine patch application.
Adverse Drug Reactions Reported With Cholinesterase Inhibitors: An Analysis of 16 Years of Individual Case Safety Reports From VigiBase.
Adverse Effects of Cholinesterase Inhibitors in Dementia, According to the Pharmacovigilance Databases of the United-States and Canada.
Age-dependent association between butyrylcholinesterase K-variant and Alzheimer disease-related neuropathology in human brains.
Age-related changes in memory and in acetylcholine functions in the hippocampus in the Ts65Dn mouse, a model of Down syndrome.
Ajmalicine and its Analogues against AChE and BuChE for the Management of Alzheimer's Disease: An In-silico study.
Alanine-to-threonine substitutions and amyloid diseases: Butyrylcholinesterase as a case study.
Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease.
Alteration of a clinically meaningful outcome in the natural history of Alzheimer's disease by cholinesterase inhibition.
Alterations in brain activation during cholinergic enhancement with rivastigmine in Alzheimer's disease.
Altered glycosylation of cerebrospinal fluid butyrylcholinesterase in Alzheimer's disease.
Altered striatal function and muscarinic cholinergic receptors in acetylcholinesterase knockout mice.
Alzheimer Disease: Pharmacologic and Nonpharmacologic Therapies for Cognitive and Functional Symptoms.
Alzheimer's dementia: current data review.
Alzheimer's disease and the glutamate NMDA receptor.
Alzheimer's disease and type 2 diabetes mellitus: the cholinesterase connection?
Alzheimer's disease in France: too many patients exposed to drug interactions involving cholinesterase inhibitors.
Alzheimer's Disease Pharmacotherapy in Relation to Cholinergic System Involvement.
Alzheimer's Disease.
Alzheimer's disease.
Alzheimer's disease: beware of interactions with cholinesterase inhibitors.
Alzheimer's disease: early diagnosis and treatment.
Alzheimer's disease: recent advances in etiology, diagnosis, and management.
Alzheimer's disease: the pharmacological pathway.
Amaryllidaceae Alkaloids of Norbelladine-Type as Inspiration for Development of Highly Selective Butyrylcholinesterase Inhibitors: Synthesis, Biological Activity Evaluation, and Docking Studies.
Amelioration of scopolamine-induced amnesia by phosphatidylserine and curcumin in the day-old chick.
Aminoalcoholate-driven tetracopper(II) cores as dual acetyl and butyrylcholinesterase inhibitors: Experimental and theoretical elucidation of mechanism of action.
Amiridine-piperazine hybrids as cholinesterase inhibitors and potential multitarget agents for Alzheimer's disease treatment.
Amyloid precursor protein 96-110 and beta-amyloid 1-42 elicit developmental anomalies in sea urchin embryos and larvae that are alleviated by neurotransmitter analogs for acetylcholine, serotonin and cannabinoids.
Amyloid processing and signal transduction properties of antiparkinson-antialzheimer neuroprotective drugs rasagiline and TV3326.
Amyloid-? peptides act as allosteric modulators of cholinergic signalling through formation of soluble BA?ACs.
An audit of a specialist old age psychiatry liaison service to a medium and a high secure forensic psychiatry unit.
An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors.
An Efficient Synthesis of bi-Aryl Pyrimidine Heterocycles: Potential New Drug Candidates to Treat Alzheimer's Disease.
An evaluation of neonicotinoids' potential to inhibit human cholinesterases: Protein-ligand docking and interaction profiling studies.
An overview of phenserine tartrate, a novel acetylcholinesterase inhibitor for the treatment of Alzheimer's disease.
An Overview on Natural Cholinesterase Inhibitors - A Multi-Targeted Drug Class - and Their Mass Production.
An update on the utility and safety of cholinesterase inhibitors for the treatment of Alzheimer's disease.
Analysis of association between Alzheimer disease and the K variant of butyrylcholinesterase (BCHE-K).
Analysis of association between butyrylcholinesterase K variant and apolipoprotein E genotypes in Alzheimer's disease.
Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial.
Analysis of the butyrylcholinesterase gene and nearby chromosome 3 markers in Alzheimer disease.
Anatomy of cholinesterase inhibition in Alzheimer's disease: effect of physostigmine and tetrahydroaminoacridine on plaques and tangles.
Antagonism of anticholinesterase (DFP) toxicity by donepezil plus scopolamine: a preliminary study.
Anti-Alzheimer potential, metabolomic profiling and molecular docking of green synthesized silver nanoparticles of Lampranthus coccineus and Malephora lutea aqueous extracts.
Anti-Alzheimer's disease activity of compounds from the root bark of Morus alba L.
Anti-Alzheimer's multitarget-directed ligands with serotonin 5-HT6 antagonist, butyrylcholinesterase inhibitory, and antioxidant activity.
Antibacterial, antioxidant, anti-cholinesterase potential and flavonol glycosides of Biscutella raphanifolia (Brassicaceae).
Anticholinesterase activity of plastoquinones from Sargassum sagamianum: lead compounds for Alzheimer's disease therapy.
Anticholinesterase-induced symptoms improved by pacemaker implantation in patients with Alzheimer's disease: analysis of 6 cases.
Antioxidant activity and acetylcholinesterase inhibition of grape skin anthocyanin (GSA).
Antioxidant and Cholinesterase Inhibitory Activity of a New Peptide From Ziziphus jujuba Fruits.
Antioxidant properties of eugenol, butylated hydroxylanisole, and butylated hydroxyl toluene with key biomolecules relevant to Alzheimer's diseases-In vitro.
Antioxidant, Antidiabetic, and Anticholinesterase Activities and Phytochemical Profile of Azorella glabra Wedd.
Apathy Treatment in Alzheimer's Disease: Interim Results of the ASCOMALVA Trial.
ApoE genotyping and response to galanthamine in Alzheimer's disease--a real life retrospective study.
Apolipoprotein ?4 modulates phenotype of butyrylcholinesterase in CSF of patients with Alzheimer's disease.
Aporphines and Alzheimer's disease: Towards a Medical Approach Facing the Future.
Aporphinoid Alkaloids Derivatives as Selective Cholinesterases Inhibitors: Biological Evaluation and Docking Study.
Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine.
Arylbenzofurans from the Root Bark of Morus alba as Triple Inhibitors of Cholinesterase, ?-Site Amyloid Precursor Protein Cleaving Enzyme 1, and Glycogen Synthase Kinase-3?: Relevance to Alzheimer's Disease.
Assessment and treatment of dementia in medical patients.
Assessment of cholinesterase and tyrosinase inhibitory and antioxidant effects of Hypericum perforatum L. (St. John's wort)
Assessment of enzyme inhibitory and antioxidant activities of lignans from Taxus baccata L.
Assessment of health economics in Alzheimer's disease (AHEAD): treatment with galantamine in the UK.
Assessment of the value of therapeutic monitoring of tacrine in Alzheimer's disease.
Association analysis between K and -116A variants of butyrylcholinesterase and Alzheimer's disease in a Brazilian population.
Association between butyrylcholinesterase and cerebrospinal fluid biomarkers in Alzheimer's disease patients.
Association between low-density lipoprotein receptor-related protein gene, butyrylcholinesterase gene and Alzheimer' s disease in Chinese.
Association of a salivary acetylcholinesterase with Alzheimer's disease and response to cholinesterase inhibitors.
Association of butyrylcholinesterase K variant with cholinesterase-positive neuritic plaques in the temporal cortex in late-onset Alzheimer's disease.
Association of Concomitant Use of Cholinesterase Inhibitors or Memantine With Cognitive Decline in Alzheimer Clinical Trials: A Meta-analysis.
Atomoxetine augmentation of cholinesterase inhibitor therapy in patients with Alzheimer disease: 6-month, randomized, double-blind, placebo-controlled, parallel-trial study.
Attainment of treatment goals by people with Alzheimer's disease receiving galantamine: a randomized controlled trial.
Attenuation of functional hyperemia to visual stimulation in mild Alzheimer's disease and its sensitivity to cholinesterase inhibition.
Australian population trends and disparities in cholinesterase inhibitor use, 2003 to 2010.
Axo-axonal interaction in autonomic regulation of the cerebral circulation.
Basal Forebrain Volume, but Not Hippocampal Volume, Is a Predictor of Global Cognitive Decline in Patients With Alzheimer's Disease Treated With Cholinesterase Inhibitors.
BCHE and CYP2D6 genetic variation in Alzheimer's disease patients treated with cholinesterase inhibitors.
Beneficial effect of cholinesterase inhibitor medications on recognition memory performance in mild to moderate Alzheimer's disease: preliminary findings.
Beneficial effect of donepezil augmentation for the management of comorbid schizophrenia and dementia.
Benefit-risk considerations in the treatment of dementia with Lewy bodies.
Benefits of cognitive-motor intervention in MCI and mild to moderate Alzheimer disease.
Benefits of combined cholinesterase inhibitor and memantine treatment in moderate-severe Alzheimer's disease.
Benzoic acid-derived nitrones: A new class of potential acetylcholinesterase inhibitors and neuroprotective agents.
Benzylpiperidine-Linked Diarylthiazoles as Potential Anti-Alzheimer's Agents: Synthesis and Biological Evaluation.
Beyond Cholinesterase Inhibition: Anti-Inflammatory Role and Pharmacological Profile of Current Drug Therapy for Alzheimer's Disease.
Beyond immunotherapy: new approaches for disease modifying treatments for early Alzheimer's disease.
Beyond the cholinergic hypothesis: the effect of metrifonate and other cholinesterase inhibitors on neuropsychiatric symptoms in Alzheimer's disease.
Biased M1-muscarinic-receptor-mutant mice inform the design of next-generation drugs.
Biochemical and Histochemical Comparison of Cholinesterases in Normal and Alzheimer Brain Tissues.
Biochemical Differentiation of Cholinesterases from Normal and Alzheimer's Disease Cortex.
Biological Activities of Aerial Parts Extracts of Euphorbia characias.
Biological Evaluation of Endophytic Fungus, Chaetomium globosum JN711454, as Potential Candidate for Improving Drug Discovery.
Biophenols: Enzymes (?-secretase, Cholinesterases, histone deacetylase and tyrosinase) inhibitors from olive (Olea europaea L.).
Blood cells cholinesterase activity in early stage Alzheimer's disease and vascular dementia.
Blood markers in Alzheimer disease: subnormal acetylcholinesterase and butyrylcholinesterase in lymphocytes and erythrocytes.
Bradycardia due to cholinesterase inhibitors: identify adverse effects and take them into account.
BuChE K variant is decreased in Alzheimer's disease not in fronto-temporal dementia.
Butyrycholinesterase K variant and Alzheimer's disease.
Butyrylcholinesterase activity, cardiovascular risk factors, and mortality in middle-aged and elderly men and women in Jerusalem.
Butyrylcholinesterase as a Diagnostic and Therapeutic Target for Alzheimer's Disease.
Butyrylcholinesterase attenuates amyloid fibril formation in vitro.
Butyrylcholinesterase genotype and gender influence Alzheimer's disease phenotype.
Butyrylcholinesterase inhibitors ameliorate cognitive dysfunction induced by amyloid-? peptide in mice.
Butyrylcholinesterase is associated with ?-amyloid plaques in the transgenic APPSWE/PSEN1dE9 mouse model of Alzheimer disease.
Butyrylcholinesterase K and Apolipoprotein ?4 Affect Cortical Thickness and Neuropsychiatric Symptoms in Alzheimer's Disease.
Butyrylcholinesterase K and Apolipoprotein E-?4 Reduce the Age of Onset of Alzheimer's Disease, Accelerate Cognitive Decline, and Modulate Donepezil Response in Mild Cognitively Impaired Subjects.
Butyrylcholinesterase K variant and Alzheimer's disease risk: a meta-analysis.
Butyrylcholinesterase K variant and apolipoprotein E4 genes do not act in synergy in Finnish late-onset Alzheimer's disease patients.
Butyrylcholinesterase K variant and cerebral amyloid angiopathy.
Butyrylcholinesterase K variant is genetically associated with late onset Alzheimer's disease in Northern Ireland.
Butyrylcholinesterase radioligands to image Alzheimer's disease brain.
Butyrylcholinesterase, ApoE and Alzheimer's disease in a population from the Canary Islands (Spain).
Butyrylcholinesterase, cholinergic neurotransmission and the pathology of Alzheimer's disease.
Butyrylcholinesterase-knockout reduces brain deposition of fibrillar ?-amyloid in an Alzheimer mouse model.
Butyrylcholinesterase: an important new target in Alzheimer's disease therapy.
Butyrylcholinesterase: impact on symptoms and progression of cognitive impairment.
Butyrylcholinesterase: K variant, plasma activity, molecular forms and rivastigmine treatment in Alzheimer's disease in a Southern Brazilian population.
Can Persistence With Cholinesterase Inhibitor Treatment Lower Mortality and Health-Care Costs Among Patients With Alzheimer's Disease? A Population-Based Study in Taiwan.
Candidate gene association studies of genes involved in neuronal cholinergic transmission in Alzheimer's disease suggests choline acetyltransferase as a candidate deserving further study.
Cannabinoid agonists showing BuChE inhibition as potential therapeutic agents for Alzheimer's disease.
Capillary zone electrophoresis determination of galanthamine in biological fluids and pharmaceutical preparatives: experimental design and artificial neural network optimization.
Carbamate derivatives of indolines as cholinesterase inhibitors and antioxidants for the treatment of Alzheimer's disease.
Carbazole-based semicarbazones and hydrazones as multifunctional anti-Alzheimer agents.
Cardiac safety of donepezil in elderly patients with Alzheimer disease.
Cardiac safety of rivastigmine in Lewy body and Parkinson's disease dementias.
Cardiovascular effects and risk of syncope related to donepezil in patients with Alzheimer's disease.
Caregiver acceptance of adverse effects and use of cholinesterase inhibitors in Alzheimer's disease.
Caregiver-specific outcomes in antidementia clinical drug trials: a systematic review and meta-analysis.
Carotid intima-media thickness as a predictor of response to cholinesterase inhibitors in Alzheimer's disease: an open-label trial.
Causes of syncope in patients with Alzheimer's disease treated with donepezil.
CDR State Transition Probabilities in Alzheimer's Disease with and without Cholinesterase Inhibitor Intervention in an Observational Cohort.
Cerebral perfusional effects of cholinesterase inhibitors in Alzheimer disease.
Cerebral white matter changes and rate of progression of dementia during cholinesterase inhibitor treatment: a retrospective cohort study.
Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer's disease.
Cerebrolysin: a review of its use in dementia.
Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors.
Cerebrovascular Pathology and Responsiveness to Treatment in Alzheimer's Disease: A Systematic Review.
Change in cognitive function according to cholinesterase inhibitor use and amyloid PET positivity in patients with mild cognitive impairment.
Changes in acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease resemble embryonic development--a study of molecular forms.
Changes in brain cholinesterases in senile dementia of Alzheimer type.
Changes in cerebral neurotransmitters and metabolites induced by acute donepezil and memantine administrations: A microdialysis study.
Changes in CSF acetyl- and butyrylcholinesterase activity after long-term treatment with AChE inhibitors in Alzheimer's disease.
Changes in metabolite ratios after treatment with rivastigmine in Alzheimer's disease : a nonrandomised controlled trial with magnetic resonance spectroscopy.
Changes in utilisation of anticholinergic drugs after initiation of cholinesterase inhibitors.
Characteristics of patients with Alzheimer's disease who switch to rivastigmine transdermal patches in routine clinical practice.
Chemical Characterization of Narcissus poeticus from Sirente -Velino (Apennines - Italy): Galantamine Accumulation and Distribution of Allergenic Compounds in the Flower.
Chemical composition of the essential oil and hexane extract of Salvia chionantha and their antioxidant and anticholinesterase activities.
Chemical composition, antioxidant and anticholinesterase activity of the essential oil of algerian cachrys sicula L.
Chemical composition, biological properties and bioinformatics analysis of two Caesalpina species: A new light in the road from nature to pharmacy shelf.
Chemistry and functional properties in prevention of neurodegenerative disorders of five Cistus species essential oils.
Chinese Medicine for Alzheimer's Disease: A Meta-Analysis of Randomized Controlled Trials.
Chlorinated tacrine analogs: Design, synthesis and biological evaluation of their anti-cholinesterase activity as potential treatment for Alzheimer's disease.
Cholinergic adverse effects of cholinesterase inhibitors in Alzheimer's disease: epidemiology and management.
Cholinergic challenge in Alzheimer patients and mild cognitive impairment differentially affects hippocampal activation--a pharmacological fMRI study.
Cholinergic enhancement of frontal lobe activity in mild cognitive impairment.
Cholinergic foundations of Alzheimer's disease therapy.
Cholinergic precursors in the treatment of cognitive impairment of vascular origin: ineffective approaches or need for re-evaluation?
Cholinergically mediated augmentation of cerebral perfusion in Alzheimer's disease and related cognitive disorders: the cholinergic-vascular hypothesis.
Cholinesterase activities in cerebrospinal fluid of patients with senile dementia of Alzheimer type.
Cholinesterase Activity and mRNA Level of Nicotinic Acetylcholine Receptors (alpha4 and beta2 Subunits) in Blood of Elderly Chinese Diagnosed as Alzheimer's Disease.
Cholinesterase activity and mRNA level of nicotinic acetylcholine receptors (alpha4 and beta2 Subunits) in blood of elderly Chinese diagnosed as Alzheimer's disease.
Cholinesterase activity in the plaques, tangles and angiopathy of Alzheimer's disease does not emanate from amyloid.
Cholinesterase and Prolyl Oligopeptidase Inhibitory Activities of Alkaloids from Argemone platyceras (Papaveraceae).
Cholinesterase as a Target for Drug Development in Alzheimer's Disease.
Cholinesterase based amperometric biosensors for assay of anticholinergic compounds.
Cholinesterase enzymes in the blood of patients with Alzheimer's disease.
Cholinesterase inhibition by derivatives of 2-amino-4,6-dimethylpyridine.
Cholinesterase inhibition for Alzheimer disease: a meta-analysis of the tacrine trials. Dementia Trialists' Collaboration.
Cholinesterase Inhibition in Alzheimer's Disease: Is Specificity the Answer?
Cholinesterase inhibition modulates visual and attentional brain responses in Alzheimer's disease and health.
Cholinesterase inhibition: is there evidence for disease-modifying effects?
Cholinesterase inhibitor affects the amyloid precursor protein isoforms in patients with Alzheimer's disease.
Cholinesterase inhibitor and N-methyl-D-aspartic acid receptor antagonist use in older adults with end-stage dementia: a survey of hospice medical directors.
Cholinesterase inhibitor blockade and its prevention by statins of sympathetic alpha7-nAChR-mediated cerebral nitrergic neurogenic vasodilation.
Cholinesterase inhibitor discontinuation in patients with Alzheimer's disease: a meta-analysis of randomized controlled trials.
Cholinesterase Inhibitor Donepezil Increases Mitochondrial Biogenesis through AMP-Activated Protein Kinase in the Hippocampus.
Cholinesterase inhibitor rivastigmine enhance the mitochondrial electron transport chain in lymphocytes of patients with Alzheimer's disease.
Cholinesterase inhibitor rivastigmine enhances nerve growth factor-induced neurite outgrowth in PC12 cells via sigma-1 and sigma-2 receptors.
Cholinesterase inhibitor therapies and neuropsychiatric manifestations of Alzheimer's disease.
Cholinesterase inhibitor therapy for Alzheimer dementia: what do animal models tell us?
Cholinesterase Inhibitor Therapy in Alzheimer's Disease: The Limits and Tolerability of Irreversible CNS-Selective Acetylcholinesterase Inhibition in Primates.
Cholinesterase inhibitor therapy stabilizes symptoms of Alzheimer disease.
Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease.
Cholinesterase inhibitor treatment and urinary incontinence in Alzheimer's disease.
Cholinesterase inhibitor use does not significantly influence the ability of 123I-FP-CIT imaging to distinguish Alzheimer's disease from dementia with Lewy bodies.
Cholinesterase inhibitor use in Alzheimer's disease: the EPIFARM-Elderly Project.
Cholinesterase inhibitor use is associated with increased plasma levels of anti-Abeta 1-42 antibodies in Alzheimer's disease patients.
Cholinesterase Inhibitor Utilization: The Impact of Provincial Drug Policy on Discontinuation.
Cholinesterase inhibitors and add-on nutritional supplements in Alzheimer's disease: a systematic review of randomized controlled trials.
Cholinesterase inhibitors and Alzheimer's disease outcomes.
Cholinesterase Inhibitors and Behavioral & Psychological Symptoms of Alzheimer's Disease.
Cholinesterase inhibitors and beyond.
Cholinesterase inhibitors and Gingko extracts--are they comparable in the treatment of dementia? Comparison of published placebo-controlled efficacy studies of at least six months' duration.
Cholinesterase inhibitors and memantine have a role in the treatment of Alzheimer's disease.
Cholinesterase inhibitors and memory.
Cholinesterase inhibitors and non-steroidal anti-inflammatory drugs as Alzheimer's disease therapies: an updated umbrella review of systematic reviews and meta-analyses.
Cholinesterase inhibitors and opiate antagonists in patients with Alzheimer's disease.
Cholinesterase inhibitors are compatible with psychosocial intervention for Alzheimer disease patients suggested by neuroimaging findings.
Cholinesterase inhibitors as adjunctive therapy in patients with schizophrenia and schizoaffective disorder: a review and meta-analysis of the literature.
Cholinesterase inhibitors do not alter the length of stay in nursing homes among patients with Alzheimer's disease: a prospective, observational study of factors affecting survival time from admission to death.
Cholinesterase inhibitors exert a protective effect on endothelial damage in Alzheimer disease patients.
Cholinesterase inhibitors for Alzheimer disease.
Cholinesterase Inhibitors for Alzheimer Disease: Do They Provide More Than Symptomatic Benefits?
Cholinesterase inhibitors for Alzheimer's disease.
Cholinesterase Inhibitors for Alzheimer's Disease: Multitargeting Strategy Based on Anti-Alzheimer's Drugs Repositioning.
Cholinesterase inhibitors for Alzheimer's disease: variations in clinical practice in the north-west of England.
Cholinesterase inhibitors for behavioral disturbance in dementia.
Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials.
Cholinesterase inhibitors for rarer dementias associated with neurological conditions.
Cholinesterase inhibitors for the treatment of Alzheimer's disease in the elderly.
Cholinesterase inhibitors for the treatment of Alzheimer's disease:: getting on and staying on.
Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis.
Cholinesterase inhibitors from the roots of Harpagophytum procumbens.
Cholinesterase inhibitors in Alzheimer's disease and Lewy body spectrum disorders: the emerging pharmacogenetic story.
Cholinesterase Inhibitors in Alzheimer's Disease.
Cholinesterase Inhibitors in Alzheimer's Disease. Proceedings of a symposium. Sweden, June 1, 1993.
Cholinesterase inhibitors in Alzheimer's disease: donepezil or rivastigmine?
Cholinesterase inhibitors in Alzheimer's disease: efficacy in a non-selected population.
Cholinesterase inhibitors in late-stage Alzheimer's disease.
Cholinesterase inhibitors in mild cognitive impairment: a systematic review of randomised trials.
Cholinesterase inhibitors in patients with diabetes mellitus and dementia: an open-cohort study of ~23 000 patients from the Swedish Dementia Registry.
Cholinesterase inhibitors in the clinical management of Alzheimer's disease: importance of early and persistent treatment.
Cholinesterase inhibitors in the treatment of Alzheimer's disease and related dementias.
Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology.
Cholinesterase inhibitors influence APP metabolism in Alzheimer disease patients.
Cholinesterase inhibitors may increase phosphorylated tau in Alzheimer's disease.
Cholinesterase Inhibitors May Not Benefit Mild Cognitive Impairment and Mild Alzheimer Disease Dementia.
Cholinesterase inhibitors modify the activity of intrinsic cardiac neurons.
Cholinesterase inhibitors proposed for treating dementia in Alzheimer's disease: selectivity toward human brain acetylcholinesterase compared with butyrylcholinesterase.
Cholinesterase inhibitors reduce aggression, wandering, and paranoia in Alzheimer disease.
Cholinesterase inhibitors slow decline in executive functions, rather than memory, in Alzheimer's disease: a 1-year observational study in the sunnybrook dementia cohort.
Cholinesterase inhibitors stabilize Alzheimer disease.
Cholinesterase inhibitors stabilize Alzheimer's disease.
Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy.
Cholinesterase inhibitors, beta-amyloid precursor protein and amyloid beta-peptides in Alzheimer's disease.
Cholinesterase inhibitors: a patent review (2007 - 2011).
Cholinesterase inhibitors: a therapeutic strategy for Alzheimer disease.
Cholinesterase Inhibitors: Cardioprotection in Alzheimer's Disease.
Cholinesterase inhibitors: new roles and therapeutic alternatives.
Cholinesterase inhibitors: tremor and exacerbation of Parkinson's disease.
Cholinesterase Inhibitory Activities of Selected Halogenated Thiophene Chalcones.
Cholinesterase Inhibitory Activity of Some semi-Rigid Spiro Heterocycles: POM analyses and Crystalline Structure of Pharmacophore Site.
Cholinesterase inhibitory activity of tinosporide and 8-hydroxytinosporide isolated from Tinospora cordifolia: In vitro and in silico studies targeting management of Alzheimer's disease.
Cholinesterase inhibitory effects of Rhizophora lamarckii, Avicennia officinalis, Sesuvium portulacastrum and Suaeda monica: Mangroves inhabiting an Indian coastal area (Vellar Estuary).
Cholinesterase Inhibitory Potential of Quercetin towards Alzheimer's Disease - A Promising Natural Molecule or Fashion of the Day? - A Narrowed Review.
Cholinesterase targeting by polyphenols: A therapeutic approach for the treatment of Alzheimer's disease.
Cholinesterase-responsive supramolecular vesicle.
Cholinesterases in cerebrospinal fluid. Correlations with clinical measures in Alzheimer's disease.
Cholinesterases in the amyloid angiopathy of Alzheimer's disease.
Cholinesterases in the cerebrospinal fluid, plasma, and erythrocytes of patients with Alzheimer's disease.
Cholinesterases within neurofibrillary tangles related to age and Alzheimer's disease.
Cholinesterases: new roles in brain function and in Alzheimer's disease.
CHRNA7 Gene and Response to Cholinesterase Inhibitors in an Italian Cohort of Alzheimer's Disease Patients.
CHRNA7 polymorphisms and response to cholinesterase inhibitors in Alzheimer's disease.
Chromone and donepezil hybrids as new multipotent cholinesterase and monoamine oxidase inhibitors for the potential treatment of Alzheimer's disease.
Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer's disease.
Chronic treatment of old rats with donepezil or galantamine: effects on memory, hippocampal plasticity and nicotinic receptors.
Clinanthus microstephus, an Amaryllidaceae species with cholinesterase inhibitor alkaloids: structure-activity analysis of haemanthamine skeleton derivatives.
Clinical and analytical considerations in the utilization of cholinesterase measurements.
Clinical Compliance of Donepezil in Treating Alzheimer's Disease in Taiwan.
Clinical meaningfulness of Alzheimer's Disease Assessment Scale-Cognitive subscale change in relation to goal attainment in patients on cholinesterase inhibitors.
Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors.
Clinical pharmacokinetics of physostigmine in patients with Alzheimer's disease.
Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology.
Clinical practice with anti-dementia drugs: a revised (second) consensus statement from the British Association for Psychopharmacology.
Clinical practice with anti-dementia drugs: A revised (third) consensus statement from the British Association for Psychopharmacology.
Clinical trials and therapy.
Clinically significant drug interactions with cholinesterase inhibitors: a guide for neurologists.
Clinicopathological correlations and cholinesterase expression in early-onset familial Alzheimer's disease with the presenilin 1 mutation, Leu235Pro.
Co-administration of memantine has no effect on the in vitro or ex vivo determined acetylcholinesterase inhibition of rivastigmine in the rat brain.
Cochrane review on 'Statins for the treatment of dementia'
Cognitive and affective changes in mild to moderate Alzheimer's disease patients undergoing switch of cholinesterase inhibitors: a 6-month observational study.
Cognitive and metabolic responses to metrifonate therapy in Alzheimer disease.
Cognitive and psychopathologic response to rivastigmine in dementia with Lewy bodies compared to Alzheimer's disease: a case control study.
Cognitive performance in Alzheimer's disease patients receiving rivastigmine for up to 5 years.
Cognitive performance in patients with Alzheimer's disease receiving cholinesterase inhibitors for up to 5 years.
Cognitive pharmacotherapy of Alzheimer's disease and other dementias.
Cognitive rehabilitation of mildly impaired Alzheimer disease patients on cholinesterase inhibitors.
Cognitive relapse after discontinuation of drug therapy in Alzheimer's disease: cholinesterase inhibitors versus nootropics.
Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis.
Combination therapy for early Alzheimer's disease: what are we waiting for?
Combination therapy with cholinesterase inhibitors and memantine for Alzheimer's disease: a systematic review and meta-analysis.
Combination treatment in Alzheimer's disease: results of a randomized, controlled trial with cerebrolysin and donepezil.
Combined in Vitro and in Silico Studies for the Anticholinesterase Activity and Pharmacokinetics of Coumarinyl Thiazoles and Oxadiazoles.
Combined Memantine and Donepezil Treatment Improves Behavioral and Psychological Symptoms of Dementia-Like Behaviors in Olfactory Bulbectomized Mice.
Combined tacrine and estrogen replacement therapy in patients with Alzheimer's disease.
Combining antioxidant astaxantin and cholinesterase inhibitor huperzine A boosts neuroprotection.
Comparative chemical profiling, cholinesterase inhibitions and anti-radicals properties of essential oils from Polygonum hydropiper L: a preliminary anti- Alzheimer's study.
Comparative effects of the alpha7 nicotinic partial agonist, S 24795, and the cholinesterase inhibitor, donepezil, against aging-related deficits in declarative and working memory in mice.
Comparative safety and effectiveness of cholinesterase inhibitors and memantine for Alzheimer's disease: a network meta-analysis of 41 randomized controlled trials.
Comparative Study of Chemical Composition, Cholinesterase Inhibition and Antioxidant Potential of Mentha pulegium L. Essential Oil.
Comparative study of selective in vitro and in silico BACE1 inhibitory potential of glycyrrhizin together with its metabolites, 18?- and 18?-glycyrrhetinic acid, isolated from Hizikia fusiformis.
Comparing treatment effects in a clinical sample of patients with probable Alzheimer's disease treated with two different cholinesterase inhibitors.
Comparison of cholinesterase inhibitor safety in real-world practice.
Comparison of cholinesterase inhibitor utilization patterns and associated health care costs in Alzheimer's disease.
Comparison of inhibitory activities of donepezil and other cholinesterase inhibitors on acetylcholinesterase and butyrylcholinesterase in vitro.
Comparison of the efficacy of four cholinesterase inhibitors in combination with memantine for the treatment of Alzheimer's disease.
Comparison of the pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy young and elderly subjects.
Comparison studies of cholinesterase inhibitors for Alzheimer's disease.
Competitive substrate inhibition in the histochemistry of cholinesterase activity in Alzheimer's disease.
Computational and experimental studies on the interaction between butyrylcholinesterase and fluoxetine: Implications in health and disease.
Computational and In-Vitro Validation of Natural Molecules as Potential Acetylcholinesterase Inhibitors and Neuroprotective Agents.
Computational and Kinetic Studies of Acetylcholine Esterase Inhibition by Phenserine.
Computational exploration and experimental validation to identify a dual inhibitor of cholinesterase and amyloid-beta for the treatment of Alzheimer's disease.
Concurrent use of anticholinergic drugs and cholinesterase inhibitors: register-based study of over 700,000 elderly patients.
Conjugates of ?-Carbolines and Phenothiazine as new selective inhibitors of butyrylcholinesterase and blockers of NMDA receptors for Alzheimer Disease.
Contemporary medicinal-chemistry strategies for the discovery of selective butyrylcholinesterase inhibitors.
Contilisant, a Tetratarget Small Molecule for Alzheimer's Disease Therapy Combining Cholinesterase, Monoamine Oxidase Inhibition, and H3R Antagonism with S1R Agonism Profile.
Continuation versus discontinuation of treatment for severe dementia: randomized, pragmatic, open-label, clinical trial to evaluate the efficacy of continuing drug treatment in patients with severe dementia (STOP-DEM).
Converting maslinic acid into an effective inhibitor of acylcholinesterases.
Correlates of response to acetylcholinesterase inhibitor therapy in Alzheimer's disease.
Cortical activation during cholinesterase-inhibitor treatment in Alzheimer disease: preliminary findings from a pharmaco-fMRI study.
Cost effectiveness of cholinesterase inhibitors in the treatment of Alzheimer's disease: a review with methodological considerations.
Cost effectiveness of donepezil in the treatment of mild to moderate Alzheimer's disease: a UK evaluation using discrete-event simulation.
Could the potential benefits of cholinesterase inhibitors in Alzheimer's disease be reduced after adjusting for coexisting diseases and multiple medications?
Coumarin, anthroquinone and stilbene derivatives with anticholinesterase activity.
Coumarins: Auspicious Cholinesterase and Monoamine Oxidase Inhibitors.
CSF biomarkers for Alzheimer's Disease: levels of beta-amyloid, tau, phosphorylated tau relate to clinical symptoms and survival.
CSF biomarkers predict a more malignant outcome in Alzheimer disease.
CSF cholinesterase in early-onset and late-onset Alzheimer's disease and multi-infarct dementia of Chinese patients.
Current and emerging pharmacological treatment options for dementia.
Current drugs and future hopes in the treatment of Alzheimer's disease.
Current issues in dementia pharmacotherapy.
Current smoking and response to cholinesterase inhibitor therapy in Alzheimer's disease.
Current Strategies and Novel Drug Approaches for Alzheimer Disease.
Current treatment of mild cognitive impairment and Alzheimer's disease.
Current treatments for Alzheimer's disease: cholinesterase inhibitors.
Cyanobiphenyls: Novel H3 receptor ligands with cholinesterase and MAO B inhibitory activity as multitarget compounds for potential treatment of Alzheimer's disease.
Decreased ratio of CSF acetylcholinesterase to butyrylcholinesterase activity in Alzheimer's disease.
Deep cerebral microbleeds are associated with poor cholinesterase inhibitor treatment response in people with Alzheimer disease.
Defining optimal treatment with cholinesterase inhibitors in Alzheimer's disease.
Defining the role of the caregiver in Alzheimer's disease treatment.
Deleterious Effect of Butyrylcholinesterase K-Variant in Donepezil Treatment of Mild Cognitive Impairment.
Dementia of Alzheimer's disease and other neurodegenerative disorders--memantine, a new hope.
Dementia with Lewy bodies: an emerging disease.
Dementia: epidemiology, intervention and concept of care.
Demonstrating the Role of Anticholinergic Activity in a Mood Disorder.
Desensitization of neuronal nicotinic receptors.
Desensitized nicotinic receptors in brain.
Design and development of novel p-aminobenzoic acid derivatives as potential cholinesterase inhibitors for the treatment of Alzheimer's disease.
Design, synthesis and biological activity of novel donepezil derivatives bearing N-benzyl pyridinium moiety as potent and dual binding site acetylcholinesterase inhibitors.
Design, synthesis and biological evaluation of bambuterol analogues as novel inhibitors of butyrylcholinesterase.
Design, synthesis and biological evaluation of new 2-benzoxazolinone derivatives as potential cholinesterase inhibitors for therapy of alzheimer's disease.
Design, synthesis and biological evaluation of novel 6H-benzo[c]chromen-6-one, and 7,8,9,10-tetrahydro-benzo[c]chromen-6-one derivatives as potential cholinesterase inhibitors.
Design, synthesis and biological evaluation of novel deoxyvasicinone-indole as multi-target agents for Alzheimer's disease.
Design, synthesis and biological evaluation of phthalimide-alkylamine derivatives as balanced multifunctional cholinesterase and monoamine oxidase-B inhibitors for the treatment of Alzheimer's disease.
Design, synthesis and biological evaluation of tacrine-1,2,3-triazole derivatives as potent cholinesterase inhibitors.
Design, synthesis and evaluation of dihydropyranoindole derivatives as potential cholinesterase inhibitors against Alzheimer's disease.
Design, synthesis and evaluation of novel cinnamic acid derivatives bearing N-benzyl pyridinium moiety as multifunctional cholinesterase inhibitors for Alzheimer's disease.
Design, synthesis and evaluation of novel indandione derivatives as multifunctional agents with cholinesterase inhibition, anti-?-amyloid aggregation, antioxidant and neuroprotection properties against Alzheimer's disease.
Design, synthesis and evaluation of novel tacrine-(?-carboline) hybrids as multifunctional agents for the treatment of Alzheimer's disease.
Design, synthesis and evaluation of novel tacrine-coumarin hybrids as multifunctional cholinesterase inhibitors against Alzheimer's disease.
Design, Synthesis, and Biological Evaluation of 1-Benzylamino-2-hydroxyalkyl Derivatives as New Potential Disease-Modifying Multifunctional Anti-Alzheimer's Agents.
Design, Synthesis, and Evaluation of Acetylcholinesterase and Butyrylcholinesterase Dual-Target Inhibitors against Alzheimer's Diseases.
Design, Synthesis, and In Vitro Biological Activities of a Bio-Oxidizable Prodrug to Deliver Both ChEs and DYRK1A Inhibitors for AD Therapy.
Design, synthesis, in vivo and in vitro studies of 1,2,3,4-tetrahydro-9H-carbazole derivatives, highly selective and potent butyrylcholinesterase inhibitors.
Design, synthesis, in vitro and in vivo evaluation of benzylpiperidine-linked 1,3-dimethylbenzimidazolinones as cholinesterase inhibitors against Alzheimer's disease.
Design, synthesis, molecular docking, and cholinesterase inhibitory potential of phthalimide-dithiocarbamate hybrids as new agents for treatment of Alzheimer's disease.
Design, synthesis, molecular modeling and neuroprotective effects of a new framework of cholinesterase inhibitors for Alzheimer's disease.
Design, synthesis, pharmacological evaluation, QSAR analysis, molecular modeling and ADMET of novel donepezil-indolyl hybrids as multipotent cholinesterase/monoamine oxidase inhibitors for the potential treatment of Alzheimer's disease.
Development and validation of a capillary zone electrophoretic method for rapid and sensitive determination of galanthamine: Application in plant and pharmaceuticals.
Development of a nanoprecipitation method for the entrapment of a very water soluble drug into Eudragit RL nanoparticles.
Development of acetophenone ligands as potential neuroimaging agents for cholinesterases.
Development of donepezil-induced hypokalemia following treatment of cognitive impairment.
Development of HuperTacrines as Non-Toxic, Cholinesterase Inhibitors for the Potential Treatment of Alzheimer's Disease.
Development of potent reversible selective inhibitors of butyrylcholinesterase as fluorescent probes.
Diabetes in a Large Dementia Cohort: Clinical Characteristics and Treatment From the Swedish Dementia Registry.
Diagnosis and management of Alzheimer disease.
Diagnosis and treatment of Alzheimer's disease.
Diagnosis and treatment of cognitive impairment.
Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients.
Differential blockade by huperzine A and donepezil of sympathetic nicotinic acetylcholine receptor-mediated nitrergic neurogenic dilations in porcine basilar arteries.
Differential CSF butyrylcholinesterase levels in Alzheimer's disease patients with the ApoE epsilon4 allele, in relation to cognitive function and cerebral glucose metabolism.
Differential distribution of butyrylcholinesterase and acetylcholinesterase in the human thalamus.
Differential effects of donepezil on methamphetamine and cocaine dependencies.
Differential laminar distribution of acetylcholinesterase and butyrylcholinesterase containing tangles in the cerebral cortex of Alzheimer's disease.
Differential levels of apolipoprotein E and butyrylcholinesterase show strong association with pathological signs of Alzheimer's disease in the brain in vivo.
Differentiated cerebrovascular effects of physostigmine and tacrine in cortical areas deafferented from the nucleus basalis magnocellularis suggest involvement of basalocortical projections to microvessels.
Differentiation Between Dementia With Lewy Bodies And Alzheimer's Disease Using Voxel-Based Morphometry Of Structural MRI: A Multicenter Study.
Dipeptidyl carboxypeptidase 1 (DCP1) and butyrylcholinesterase (BCHE) gene interactions with the apolipoprotein E epsilon4 allele as risk factors in Alzheimer's disease and in Parkinson's disease with coexisting Alzheimer pathology.
Discontinuation of cholinesterase inhibitor treatment and determinants thereof in the Netherlands: A retrospective cohort study.
Discontinuation of donepezil for the treatment of Alzheimer's disease in geriatric practice.
Discontinuation, efficacy and safety of cholinesterase inhibitors for Alzheimer's disease: a meta-analysis and meta-regression of 44 randomized clinical trials enrolling 16,245 patients.
Discontinuing cholinesterase inhibitors: results of a survey of Canadian dementia experts.
Discorhabdin alkaloids from Antarctic Latrunculia spp. sponges as a new class of cholinesterase inhibitors.
Discovery and Structure-Activity Relationships of a Highly Selective Butyrylcholinesterase Inhibitor by Structure-Based Virtual Screening.
Discovery of 9-phenylacridinediones as highly selective butyrylcholinesterase inhibitors through structure-based virtual screening.
Discovery of Butyrylcholinesterase-Activated Near-Infrared Fluorogenic Probe for Live-Cell and In Vivo Imaging.
Discovery of drug-like acetylcholinesterase inhibitors by rapid virtual screening of a 6.9 million compound database.
Discovery of Highly Selective and Nanomolar Carbamate-Based Butyrylcholinesterase Inhibitors by Rational Investigation into Their Inhibition Mode.
Discovery of isoalloxazine derivatives as a new class of potential anti-Alzheimer agents and their synthesis.
Discovery of new butyrylcholinesterase inhibitors via structure-based virtual screening.
Discovery of Novel Pyrazolopyrimidinone Derivatives as Phosphodiesterase 9A Inhibitors Capable of Inhibiting Butyrylcholinesterase for Treatment of Alzheimer's Disease.
Discovery of potent and selective butyrylcholinesterase inhibitors through the use of pharmacophore-based screening.
Discovery of sustainable drugs for Alzheimer's disease: cardanol-derived cholinesterase inhibitors with antioxidant and anti-amyloid properties.
Discovery, biological evaluation and molecular dynamic simulations of butyrylcholinesterase inhibitors through structure-based pharmacophore virtual screening.
Discovery, biological evaluation, and crystal structure of a novel nanomolar selective butyrylcholinesterase inhibitor.
Disease stage in Alzheimer disease and treatment effects of rivastigmine.
Distribution of butyrylcholinesterase in the human amygdala and hippocampal formation.
Distribution of m1 muscarinic acetylcholine receptors in the hippocampus of patients with Alzheimer's disease and dementia with Lewy bodies-an immunohistochemical study.
DL0410 can reverse cognitive impairment, synaptic loss and reduce plaque load in APP/PS1 transgenic mice.
Do blood pressure and age predict response to tacrine (THA) in Alzheimer's disease? A preliminary report.
Do Cholinesterase Inhibitors Act Primarily on Attention Deficit? A Naturalistic Study in Alzheimer's Disease Patients.
Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer's disease?
Donepezil and life expectancy in Alzheimer's disease: A retrospective analysis in the Tajiri Project.
Donepezil and memantine for moderate-to-severe Alzheimer's disease.
Donepezil and Rivastigmine: Pharmacokinetic Profile and Brain-targeting After Intramuscular Administration in Rats.
Donepezil blocks voltage-gated ion channels in rat dissociated hippocampal neurons.
Donepezil dosing strategies: pharmacokinetic considerations.
Donepezil Effects on Hippocampal and Prefrontal Functional Connectivity in Alzheimer's Disease: Preliminary Report.
Donepezil for Alzheimer's disease.
Donepezil improves learning and memory deficits in APP/PS1 mice by inhibition of microglial activation.
Donepezil in low micromolar concentrations modulates voltage-gated potassium currents in pyramidal neurons of rat hippocampus.
Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study.
Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASIL.
Donepezil in the treatment of patients with Alzheimer's disease.
Donepezil markedly potentiates memantine neurotoxicity in the adult rat brain.
Donepezil modulates nicotinic receptors of substantia nigra dopaminergic neurones.
Donepezil overdose: a tenfold dosing error.
Donepezil Treatment for Alzheimer's Disease in Chronic Dialysis Patients.
Donepezil use for advanced Alzheimer's disease--a case study from a long-term care facility.
Donepezil use in Alzheimer disease.
Donepezil versus vitamin E in Alzheimer's disease: Part 2: mild versus moderate-severe Alzheimer's disease.
Donepezil, a cholinesterase inhibitor used in Alzheimer's disease therapy, is actively exported out of the brain by abcb1ab p-glycoproteins in mice.
Donepezil, rivastigmine, and vitamin E in Alzheimer disease: a combined P300 event-related potentials/neuropsychologic evaluation over 6 months.
Donepezil-based multi-functional cholinesterase inhibitors for treatment of Alzheimer's disease.
Donepezil-induced cervical dystonia in Alzheimer's disease: a case report and literature review of dystonia due to cholinesterase inhibitors.
Donepezil-induced improvement in delayed matching accuracy by young and old rhesus monkeys.
Donepezil-related toxic hepatitis.
Donepezil: potential neuroprotective and disease-modifying effects.
Dose and plasma concentration of galantamine in Alzheimer's disease - clinical application.
Double-blind placebo-controlled study of velnacrine in Alzheimer's disease.
Drug Design of Inhibitors of Alzheimer's Disease (AD): POM and DFT Analyses of Cholinesterase Inhibitory Activity of ?-amino di-Carbonyl Derivatives.
Drug interactions with cholinesterase inhibitors.
Drug persistency of two cholinesterase inhibitors: rivastigmine versus donepezil in elderly patients with Alzheimer's disease.
Drug persistency patterns for patients treated with rivastigmine or donepezil in usual care settings.
Drug Profile: Transdermal Rivastigmine Patch in the Treatment of Alzheimer Disease.
Drug-induced urinary incontinence.
Drugs and falls in community-dwelling older people: a national veterans study.
Drugs for Alzheimer's disease. Guidelines for prescribing cholinesterase inhibitors in Australia are similar to those in UK.
Drugs for Alzheimer's disease: best avoided. No therapeutic advantage.
Dual functional cholinesterase and MAO inhibitors for the treatment of Alzheimer's disease: synthesis, pharmacological analysis and molecular modeling of homoisoflavonoid derivatives.
Dual functional cholinesterase and PDE4D inhibitors for the treatment of Alzheimer's disease: Design, synthesis and evaluation of tacrine-pyrazolo[3,4-b]pyridine hybrids.
Dual inhibitors of monoamine oxidase and cholinesterase for the treatment of Alzheimer disease.
Dual monoamine oxidase and cholinesterase Inhibitors with different heterocyclic scaffolds.
Dual-acting agents for improving cognition and real-world function in Alzheimer's disease: Focus on 5-HT6 and D3 receptors as hubs.
Duration of therapy with acetylcholinesterase inhibitors in patients with mild-to-moderate Alzheimer's disease as reported in the literature.
Early- versus late-onset Alzheimer's disease in clinical practice: cognitive and global outcomes over 3 years.